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Abstract: Two sensitive and validated methods were developed for determination of a racemic mixture citalopram and its 
enantiomer S-(+) escitalopram. The ﬁ  rst method was based on direct measurement of the intrinsic ﬂ  uorescence of escitalo-
pram using sodium dodecyl sulfate as micelle enhancer. This was further applied to determine escitalopram in spiked human 
plasma, as well as in the presence of common and co-administerated drugs. The second method was TLC densitometric 
based on various chiral selectors was investigated. The optimum TLC conditions were found to be sensitive and selective 
for identiﬁ  cation and quantitative determination of enantiomeric purity of escitalopram in drug substance and drug products. 
The method can be useful to investigate adulteration of pure isomer with the cheap racemic form.
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Introduction
Citalopram (Fig. 1) a selective serotonine re-uptake inhibitor (SSRI), has been used for the treatment 
of depression, social anxiety disorder, panic disorder and obsessive-compulsive disorder.
1–3 Citalopram 
is sold as a racemic mixture, consisting of 50% R-(−)-citalopram and 50% S-(+)-citalopram. As the 
S-(+) enantiomer has the desired antidepressant effect
4 it is now marketed under the generic name of 
escitalopram. It has been shown that the R-enantiomer present in citalopram counteracts the activity of 
escitalopram. Citalopram and escitalopram have demonstrated different pharmacological and clinical 
effects.
5
A number of techniques including spectrophotometric,
6,7 ﬂ  uorimetric,
8,9 electrochemical,
10 chroma-
tography
11,12 and capillary electrophoresis
13,14 have been developed for the determination of enantiomeric 
citalopram. Although several chiral methods including LC
15–20 and CE
21,22 are available for separation 
of racemic citalopram, there is no report concerning enantiomeric separation of citalopram using thin 
layer chromatography (TLC).
In this study we develop two simple, economic and validated methods for determination of escitalo-
pram and enantioseparation of its racemic mixture in drug substance and drug products. The ﬂ  uorimet-
ric method was based on the ﬂ  uorescence spectral behavior of escitalopram in micellar systems, such as 
Triton
® X-100, Cetylpyridinium bromide; and sodium dodecyl sulfate (SDS). The ﬂ  uorescence intensity 
of escitalopram and its racemic mixture citalopram was compared under the same experimental condi-
tions. The method was successfully applied to the analysis of escitalopram in drug substances, drug 
product as well as spiked human plasma. Furthermore, the method was found to tolerate high concentra-
tions of co-administrated and common drugs without potential interference. In addition to the ﬂ  uorimet-
ric method, TLC densitometry was proposed for stereoselective separation of (±) citalopram and 
determination of its enantiomer, escitalopram, using the different chiral selectors namely, brucine sulphate, 
chondroitin sulphate, heparin sodium and hydroxypropyl-β-cyclodextrin (HP-β-CD). The developed 
TLC method based on chiral mobile phase additives (CMPAs), tend to be cheap and feasible and offer 
a potential strategy for simultaneous separation of different chiral drugs on the same plate. The method 
was validated according to ICH guidelines and can become the method of choice compared to other 
techniques for fast routine enantiomeric analysis.2
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Experimental
Instrumentation
Waters-2525 LC system, equipped with a dual wave-
length absorbance detector 2487, an auto-sampler 
injector and Mass Lynx v 4.1, was used. The LC 
column was C18 reverse-phase column (4.6 mm 
diameter × 100 mm length, 5 μm particles, 
phenomenex, monolithic).
1 H-NMR spectra were 
recorded on Bruker Avance-400 spectrometer 
operating at 400 MHz. FT-IR spectrometer Avatar 
360 was used. Spectroﬂ  uorimetric measurement was 
carried out using a Shimadzu spectroﬂ  uorimeter 
Model RF-1501 equipped with xenon lamp and 1-cm 
glass cells. Excitation and emission wavelengths 
were set at 242 nm and 306 nm respectively. Pre-
coated TLC plates (10 × 10 cm, aluminum plate 
coated with 0.25 mm silica gel F254) were purchased 
from Merck Co., Egypt. Samples were applied to the 
TLC plates with 25 μL Hamilton microsyringe. UV 
short wavelength lamp (Desaga Germany) and Shi-
madzu dual wavelength ﬂ  ying spot densitometer, 
Model CS-9301, PC were used. The experimental 
conditions of the measurements were as follows: 
wavelength = 240 nm, photo mode = reﬂ  ection, scan 
mode = zigzag, and swing width = 10.
Chemicals and reagents
All chemicals used were of analytical grade if not 
stated otherwise. Escitalopram oxalate (Alkan Pharm 
Co., Egypt) certiﬁ  ed to contain 99.60% was used as 
the reference standard. Cipralex containing 10 mg 
escitalopram oxalate per tablet (manufactured by 
Lund beck Co., Denmark, Batch No 2147226, Mfg. 
D: 2008, Exp. D: 2011) was purchased from the 
market. Escitalopram oxalate was extracted and 
puriﬁ  ed from cipralex tablets. Citalopram was kindly 
supplied by Adwia Co., Egypt. Its purity was found 
to be 99.80% according to ofﬁ  cial HPLC method.
23 
Lecital, containing 40 mg citalopram hydrobromide 
per tablet (manufactured by Joswe Medical Co., 
Jordon) was purchased from the market. Human 
plasma was kindly supplied from Vacsera, Egypt. 
Sodium dodecyl sulfate (BHD, Egypt), brucine 
sulphate (BHD, Egypt), chondroitin sulfate, (Eva 
Co., Egypt), heparin sodium and 2-hydroxypropyl-
β-cyclodextrin (Fluka, Egypt) were purchased. 
Triﬂ  uoroacetic acid (Aldrich, U.K), methanol and 
acetonitrile (Fisher Scientiﬁ  c, U.K.) were LC grade. 
Ultra pure water (ELGA, U.K.) was used.
Extraction of escitalopram 
from cipralex tablets
Ten cipralex tablets were ﬁ  nely powdered and trans-
ferred to a 100 mL conical ﬂ  ask to which 50 mL 
methanol was added and stirred for 20 min. The 
solution was ﬁ  ltered through whatman No. 42 ﬁ  lter 
paper. The residue was washed several times with 
small volume of methanol for complete recovery. 
The combined extract was evaporated and the pure 
sample was obtained by recryslallization from 
methanol.
Characterization of isolated escitalopram
The weight of escitalopram oxalate obtained by 
extraction and recrystalization was the same as the 
labeled value. Characterization of the extracted 
escitalopram was done using UV, TLC, LC-MS 
and NMR.
Absorbance spectra were recorded in methanol 
and TLC separation was carried out using toluene-
ethyl acetate-triethylmine (7:3.5:3 v/v/v) as the 
mobile phase.
11 LC-MS was used for establishing 
the purity of escitalopram using a reverse phase C18 
column at ﬂ  ow rate of 1 ml/min and acetonitrile:
water:trifluoroacetic acid (60:40:0.01% v/v/v) 
mobile phase. Further characterization included 
FT-IR, 
1H-NMR in deuterated methanol (CD3OD).
Standard solutions
Standard stock solutions of (±)citalopram hydrobro-
mide, and S-(+)escitalopram oxalate 0.05 mg mL
−1 
and 4 mg mL
−1 were prepared by dissolving appro-
priate amounts of each in water and methanol for 
ﬂ  uorimetric and TLC methods respectively. The 
stock solutions were subsequently used to prepare 
working standards in methanol. All solutions were 
stored in refrigerator at 4 
οC.
Synthetic mixtures
For TLC method, synthetic mixtures of escitalo-
pram and citalopram in proportions ranging from 
O
F
N
CN
O
F
N
CN
S -Escitalopram R-Citalopram
Figure 1. Chemical structure of citalopram enantiomers.3
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10%–90% were analyzed and the percentage 
recovery of escitalopram was calculated.
Method development
Spectroﬂ  uorimetric method
1 mL of aqueous stock solution equivalent 
to (1.25–162.5 μg mL
−1) of escitalopram or 
(1.25–125.0 μg mL
−1) citalopram was transferred 
into a series of 10 mL volumetric ﬂ  asks followed 
by 1 mL SDS (5 mmol aqueous solution). The 
volume was completed to the mark with methanol. 
The ﬂ  uorescence was measured at 306 nm using 
242 nm as excitation wavelength. To obtain the 
standard calibration graph, concentrations were 
plotted against ﬂ  uorescence intensity and the linear 
regression equations were computed.
TLC method
Chromatograms were developed in clean, dry, 
paper-lined glass chambers (12 × 24 × 24 cm) 
pre-equilibrated with developer for 10 minutes. 
The TLC plates were prepared by running the 
mobile phase of acetonitrile-water (17:3 v/v) con-
taining 1 mmol chiral selector to the lost front in 
the usual ascending way and were air-dried. For 
detection and quantiﬁ  cation, 10 μL each of cital-
opram and escitalopram solutions within the 
quantiﬁ  cation range were applied side-by-side as 
separate compact spots 20 mm apart and 10 mm 
from the bottom of the TLC plates using a 25 μL 
Hamilton micro syringe. The chromatograms were 
developed up to 8 cm in the usual ascending way 
using the same mobile phase omitting the chiral 
selectors, and were then air dried. The plates were 
visualized at 254 nm or by exposure to I2 vapor 
and scanned for escitalopram at wavelength 
240 nm using the instrumental parameters men-
tioned above.
For quantitative determination of escitalopram 
aliquots of standard solution (4 mg mL
−1) equiv-
alent to 0.125–4.000 mg were transferred into 
10 mL volumetric ﬂ  asks and made up to volume 
with methanol. 10 μL of each concentration was 
applied on the TLC plate, air dried and scanned 
for escitalopram at 240 nm using the instrumental 
parameters mentioned above. The average peak 
areas were calculated and plotted against concen-
tration. The linear relationship was obtained and 
the regression equation was recorded.
Application to tablets
An accurately weighed amount of powdered tablets 
equivalent to 100 mg of escitalopram and citalopram 
were dissolved in 50 mL methanol. The solutions 
were stirred with magnetic stirrer for 20 min. Each 
solution was transferred quantitatively to a 50 mL 
volumetric ﬂ  ask, diluted to the volume with metha-
nol, and ﬁ  ltered. For ﬂ  uorimetric analysis, a portion 
equivalent to 25 mg was evaporated, transferred 
quantitatively to a 50 mL volumetric ﬂ  ask and made 
up to volume with water. The procedure was com-
pleted as mentioned above.
Application to spiked human plasma
Aliquots equivalent to 0.1–0.4 mg mL
−1 of esci-
talopram were sonicated with 1 mL plasma for 
5 minutes. Acetonitrile (2 mL) was added and then 
centrifuged for 30 minutes. One milliliter of super-
natant was evaporated and the procedure was 
completed as described above.
Results and Discussion
In this work a simple method was used for isolation 
of escitalopram from its drug product rather than 
the published procedure.
24 The isolated escitalo-
pram was characterized and conﬁ  rmed by different 
analytical techniques as mentioned above.
Fluorimetric method
Escitalopram solution was found to exhibit an 
intense ﬂ  uorescence at a wavelength of 306 nm on 
excitation at 242 nm as shown in Figure 2. Differ-
ent media such as water, methanol and ethanol were 
attempted. Maximum ﬂ  uorescence intensity was 
obtained upon using methanol as diluting solvent, 
while water decreases the ﬂ  uorescence intensity.
The effect of different surfactants on the ﬂ  uo-
rescence intensity of escitalopram was studied by 
adding 1 mL of each surfactant to the aqueous drug 
solution. CPB and Triton X-100 led to peak broad-
ening and no effect on ﬂ  uorescence intensity, while 
SDS caused two fold increasing in the intensity. 
The ﬂ  uorescence intensity was stable for at least 
two hours.
When compared to its racemic form, escitalo-
pram showed a lower ﬂ  uorescence intensity. This 
is concordance with published data giving the molar 
absorbitivity of escitalopram as 13.630 mol
−1cm
−1 
while that of citalopram is 15.630 mol
−1cm
−1.
8 
The quantum yield was found to be 0.026 for 4
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escitalopram and 0.030 for citalopram according 
to the following equation.
25
Yu = Ys . Fu/Fs . As/Au
where Yu and Ys referred to ﬂ  uorescence quantum 
yield of escitalopram and quinine sulphate, respec-
tively; Fu and Fs represented the integral ﬂ  uores-
cence intensity of escitalopram and quinine 
sulphate, respectively; Au and As referred to the 
absorbance of escitalopram and quinine sulphate 
at the excited wavelength respectively.
The method was validated by testing linearity, 
speciﬁ  city, precision and reproducibility as pre-
sented in (Table 1).
Calibration plot was found to hold good over a 
concentration range of 0.125–16.25 μg mL
−1 and 
0.125–12.50 μg mL
−1 for escitalopram and citalo-
pram respectively. The procedure gave good repro-
ducibility when applied to escitalopram drug 
substance over three concentration levels; 3.30, 
6.60 and 13.30 μg mL
−1. Whereas the speciﬁ  city 
was proved by quantitate the studied drug in its 
tablet form, confirming non-interference from 
excipients and additives.
The results were comparable to those given by 
a reported method
8 as revealed by statistical analy-
sis adopting Student’s t- and F-tests, where no 
signiﬁ  cant difference was noticed between the two 
methods as presented in (Table 2). The validity of 
the procedure was further assured by the recovery 
of the standard addition. The limit of detection 
(LOD) and the limit of quantiﬁ  cation (LOQ) were 
found to be 0.017 and 0.056 μgmL
−1 respectively.
The high sensitivity attained by the ﬂ  uorimetric 
procedure allowed its successful application to the 
analysis of escitalopram in spiked human plasma. 
To avoid variation in background ﬂ  uorescence, a 
simple deproteination of plasma samples with 
acetonitrile was performed followed by centrifuga-
tion, the clear supernatant containing escitalopram 
was analyzed. A calibration graph was obtained by 
spiking plasma samples with escitalopram in the 
range 3.30–16.25 μg mL
−1. Linear regression 
analysis of the data gave the equation
FI = 37.27 C + 126
r = 0.991 (n = 6)
where FI is the ﬂ  uorescence intensity, C is the 
concentration of escitalopram in plasma in μg mL
−1 
and r is correlation coefﬁ  cient. The limit of detec-
tion and quantiﬁ  cation in spiked plasma were found 
to be 0.17 μg mL
−1 and 0.56 μg mL
−1. The average 
recovery was 98.00% ± 2.80% RSD. The results 
from analysis of 5 spiked plasma samples are pre-
sented in Table 2.
The interference due to co-administrated and com-
mon drugs was investigated in mixed solutions con-
taining 5 μg mL
−1 escitalopram and different 
concentrations of an interferant. The resulting 
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Figure 2. Fluorescence spectra of 10 μg mL
−1 escitalopram oxalate a) in methanolic medium b) in 5 mM SDS micellar medium c) spiked 
plasma sample (6.6 μg mL
−1) in 5 mM SDS micellar medium d) blank plasma sample.5
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Table 1. Validation report on the ﬂ  uorimetric and TLC-densitometric methods for the determination of escitalopram 
in drug substance.
Parameters Fluorimetric method TLC-method
Linearity range 0.125–16.250 μg mL
-1 0.50–40.00 μg/spot
Regression equation
 Slope 55.556 264.240
  SE of Slope 0.513 2.460
Intercept 25.466 195.730
  SE of Intercept 5.377 50.470
Correlation Coefﬁ  cient (r) 0.9998 0.9997
  SE of estimation 8.438 102.360
Accuracy
 Mean
a ± RSD% 99.71 ± 1.05 100.10 ± 1.63
Precision (Mean ± RSD%)
 Intra-day
b 99.40 ± 0.41 100.08 ± 1.38
 Inter-day
b 99.54 ± 1.08 99.70 ± 2.09
LOD 0.017 0.014
LOQ 0.056 0.046
an = 6; 
bn = 9.
Table 2. Analytical applications of ﬂ  uorimetric method.
Forms Fluorimetric method Reported 
method
a (8)
Drug substance
Mean 99.71 99.28
SD 1.05 0.81
V 1.10 0.66
SE 0.40 0.31
n7 7
t-test (2.228)
b 0.84
F-test (4.53)
b 1.67
Cipralex tablet 
10 mg/tablet, escitalopram 
oxalate
Recovery
c ± RSD% Added μg mL
–1 Found recovery
c ± 
RSD%
0.250 101.60 ± 0.85 97.30 ± 1.98
98.90 ± 1.22 5.000 99.00 ± 1.06
12.500 100.9 ± 1.57
Spiked plasma Recovery
c ± RSD%
Drug substance 98.00 ± 2.80 –
Cipralex tablet 
10 mg/tablet, escitalopram 
oxalate
90.00 ± 3.50
aSpectrophotometric method.
bTheoretical values, at P = 0.05.
cMean of four experiments.6
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ﬂ  uorescence was compared to those obtained for 
escitalopram only at the same concentration. 
Tolerance was deﬁ  ned as the amount of interferant 
that produced an error not exceeding 5% in determi-
nation of the analyte. The method was found to be 
selective enough to tolerate high concentration of 
co-administerated and common drugs. Table 3, shows 
the maximum tolerable weight ratio for these drugs.
The ﬂ  uorimetric method offers simplicity, rapid 
response and the potential to be efﬁ  cient for bio-
availability assessments and therapeutic drug 
monitoring of patients treated with citalopram or 
escitalopram.
TLC-densitometric method
Compared to other chromatographic techniques, 
TLC is a simple, economical, rapid and ﬂ  exible 
technique allowing sensitive parallel processing of 
many samples on one plate. For enantiomeric 
separation, chiral stationary phases and mobile 
phase additives can be used. Brucine, chondroitin, 
heparin and HP-β-CD were used as chiral selectors 
for enantiomeric separation of different pharma-
ceutical compounds using TLC, LC and CE.
26–28
The literature reveals that chiral recognition may 
occur due to formation of inclusion complexes, 
hydrogen-bonding, π–π interaction, hydrophobic 
interaction or steric repulsion.
29 For instance, enan-
tioselectivity using brucine arises due to the forma-
tion of two diastereomers through simple ionic 
interactions between racemate and chiral selector, 
e.g. (+)-citalopram/brucine and (−)-citalopram/
brucine.
30 The enantiomeric resolution by HP-β-CD 
may involve the inclusion of drug within the CD 
cavity relative to the comparability of sizes, shapes 
and hydrophibicities. Whereas steric effect derived 
from the anion of chondroitin sulphate contributes 
mainly to the interactions with drug enantiomer,
31 
the chiral discriminating capability of heparin is 
believed to be due to formation of a helical structure 
in aqueous solution.
In this work, TLC methodology was developed 
for separation of (±) citalopram and determination 
of escitalopram using different chiral selectors, the 
method depending on the difference in Rf values of 
(R)- and (S)- forms of (±) citalopram. The experi-
mental conditions such as mobile phase composition, 
chiral selector, pH and temperature were optimized 
to provide accurate, precise, reproducible and robust 
separation. Various chiral mobile phase additives 
including brucine sulphate, chondroitin sulphate, 
heparin sodium and HP-β-CD were tested. The best 
resolution was achieved by using 1 mM of brucine 
sulphate in acetonitrile:water (17:3 v/v) as a mobile 
phase (Table 4). The order of enantioselectivity was 
found to be brucine sulphate  HP-β-CD  heparin 
sodium  chondroitin sulphate as shown in Figure 3. 
The Rf values were 0.17, 0.22, 0.22, 0.29 for esci-
talopram and 0.71, 0.70, 0.66, 0.77 for (R)-citalopram 
Table 3. Interference study of different compounds in 
the determination of 5 μg mL
−1 of escitalopram by ﬂ  uo-
rimetric method.
Drugs Tolerated 
interference/analyte 
ratio
a (w/w)
1.Co-administerated
 Paroxetine  HCl  100
 Loratadine  100
 Propranolol 20
 Alprazolam 100
2.Common
 Pseudoephedrine  HCl  100
 Aspirin 100
 Ibuprofen 50
aMaximum ratio tested.
Table 4. Effect of mobile phase system on enantiomeric resolution of RS-citalopram and S-escitalopram 
(20 μg/spot), using brucine (1 mM) as chiral selector.
Mobile phase system 
CH3CN:CH3OH:H2O
Rf values Rf(R)/Rf(S)
Pure Racemic mixture
S-(+) R-(−) S-(+)
16:1:3 0.22 0.80 0.22 3.64
17:0:3 0.17 0.71 0.17 4.18
20:4:0 0.26 0.75 0.26 2.887
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for the four selected chiral additives respectively 
as shown in Figure 4. Due to it’s lower health risks, 
HP-β-CD was chosen over brucine sulphate for the 
determination of escitalopram. We also investigated 
the effect of pH and temperature on resolution of 
racemic citalopram as they have been known to affect 
chiral recognition.
26 The best conditions for dis-
crimination of citalopram enantimers were found at 
pH 8.0 and 25 ± 2 
οC.
Method validation
The method was validated according to ICH 
regulations by documenting its linearity, accuracy, 
precision, limit of detection and quantiﬁ  cation, 
speciﬁ  city and, robustness.
30,33 The good linearity 
was obtained for seven concentrations in the range 
of 0.5– 40 μg/spot as shown in Figure 5. The accu-
racy based on the mean percentage of measured 
concentrations (n = 6) to the actual concentration 
is stated in (Table 1). The precision of the method 
was assessed by determining RSD% values of intra-
and inter-day analysis (n = 9) of escitalopram over 
three days. Two different analysts performed inter-
mediate precision experiments with separate mobile 
phase systems according to the proposed procedure. 
The RSD% values of the intermediate precision are 
less than 2% for drug substance and drug product. 
The LOD and LOQ were found to be 0.014 and 
0.076 μg/spot respectively (Table 1). The speciﬁ  c-
ity of the method was assessed by analyzing syn-
thetic mixtures of escitalopram and citalopram in 
different proportions as shown in (Table 5). The 
conditions for this method were modiﬁ  ed slightly 
with respect to mobile phase ratio, pH and tem-
perature, the results indicating its ability to remain 
unaffected by small changes in the method's param-
eters, thus the method is considered robust.
The standard addition recoveries were carried 
out by adding a known amount of escitalopram to 
the powdered tablets at three different levels (5, 10 
and 20 μg) with each level in triplicates (n = 3). 
The recovery percentage was evaluated by the ratio 
of the amount found to added. The average recov-
ery was calculated and presented in (Table 6).
Conclusion
The present work makes use of micelle enhanced 
intrinsic ﬂ  uorescence of escitalopram for its 
Figure 3. Effect of chiral selectors (1 mM) on enantiomeric resolution 
of racemic citalopram hydrobromide by silica gel TLC (20 μg/spot).
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Figure 4. Thin layer chromatogram showing resolution of racemic citalopram hydrobromide, 20 μg/spot using different chiral selectors 1 mM, 
a) brucine sulphate, b) chondroitin sulfate c) heparin sodium, d) HP-β-CD; acetonitrile:water (17:3 v/v); solvent front 8 cm, 25 ± 2 
οC, com-
pared with control without chiral selector.8
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Figure 5. Densitometric scanning proﬁ  le for TLC-chromatogram of different concentrations of escitalopram oxalate, (0.5–40 μg/spot) at 
240 nm.
Table 5. Determination of escitalopram in presence of racemic citalopram in synthetic mixtures by TLC Method.
Sample Escitalopram:
citalopram (μg: μg)
Recovery
a (%) RSD (%)
1 36:4 98.00 1.48
2 16:24 99.13 0.23
3 32:8 98.33 1.66
4 4:36 98.44 1.98
aAll measurements were made in triplicates, 25 
οC ± 2 
οC.
determination in drug substance, commercial 
tablets and spiked human plasma. It was found 
to be selective and tolerate high concentrations 
of other co-administrated and common drugs. 
The TLC method developed was effective for 
enantioseparation and determination of 
enantiomers of citalopram. A comparative study 
using different chiral selectors was described 
with the methods being completely validated, 
showing satisfactory data for all validation 
parameters tested. Both methods offer simplicity, 
rapid response and economy.
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Table 6. Analysis results for determination of escitalopram in cipralex tablets and application of standard addition 
technique by TLC method.
Sample Recovery
a ± RSD% Standard addition
Escitalopram authentic 
added μg/spot
Found recovery
a ± RSD%
1 100.52 ± 0.97 5 102.00 ± 2.09
2 101.19 ± 1.29 10 101.87 ± 1.99
3 98.45 ± 0.59 20 98.71 ± 1.07
an = 3.